What type of therapy does imatinib represent in oncology?

What type of therapy does imatinib represent in oncology?

• A. Monoclonal antibody therapy
• B. Tyrosine kinase inhibitor therapy
• C. Radiotherapy
• D. Chemotherapy

Answer: (B)

Imatinib is classified as a tyrosine kinase inhibitor therapy, which plays a critical role in oncology, particularly in the treatment of certain types of cancer such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This therapy works by targeting specific proteins involved in the signaling pathways that regulate cell growth and division. By inhibiting the activity of the BCR-ABL fusion protein, which is a result of the Philadelphia chromosome translocation in CML, imatinib effectively reduces the proliferation of malignant cells. Tyrosine kinase inhibitors like imatinib are designed to block the action of tyrosine kinases, which are enzymes responsible for the phosphorylation of tyrosine residues on proteins, facilitating various signaling pathways integral to cancer development and progression. This targeted approach contrasts with broader treatment modalities, such as traditional chemotherapy, which often impacts both cancerous and normal cells leading to a wider range of side effects. Furthermore, unlike monoclonal antibody therapy that typically targets antigens on the surface of cancer cells or boosts the immune response, or radiotherapy which utilizes high-energy particles or waves to destroy cancer cells through damaging their DNA, imatinib provides a more focused mechanism of action against specific molecular targets. Its

Imatinib is classified as a tyrosine kinase inhibitor therapy, which plays a critical role in oncology, particularly in the treatment of certain types of cancer such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This therapy works by targeting specific proteins involved in the signaling pathways that regulate cell growth and division. By inhibiting the activity of the BCR-ABL fusion protein, which is a result of the Philadelphia chromosome translocation in CML, imatinib effectively reduces the proliferation of malignant cells.

Tyrosine kinase inhibitors like imatinib are designed to block the action of tyrosine kinases, which are enzymes responsible for the phosphorylation of tyrosine residues on proteins, facilitating various signaling pathways integral to cancer development and progression. This targeted approach contrasts with broader treatment modalities, such as traditional chemotherapy, which often impacts both cancerous and normal cells leading to a wider range of side effects.

Furthermore, unlike monoclonal antibody therapy that typically targets antigens on the surface of cancer cells or boosts the immune response, or radiotherapy which utilizes high-energy particles or waves to destroy cancer cells through damaging their DNA, imatinib provides a more focused mechanism of action against specific molecular targets. Its